SCHEMBL7468533

SCHEMBL7468533

OC[C@@H](O)c1ccccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.56
ADRB1 P08588 2/20 0.56
AOC3 Q16853 1/20 0.56
HIF1A Q16665 3/20 0.55
CYP2D6 P10635 2/20 0.55
NFKB1 P19838 1/20 0.55
BLM P54132 2/20 0.53
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
CYP1A2 P05177 1/20 0.46
NISCH Q9Y2I1 1/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ACP3 P15309 1/20 0.40
CASP1 P29466 1/20 0.40
TSHR P16473 3/20 0.39
LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4298647 1.00 ADRB2 (0.56) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL382030 1.00 ADRB2 (0.56) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL29711020 1.00 ADRB2 (0.56) ADRB2ADRB1AOC3HIF1ACYP2D6
Bicarbonate SCHEMBL8740961 0.92 ADRB2 (0.50) ADRB2ADRB1AOC3HIF1ACYP2D6
Bicarbonate SCHEMBL8741303 0.92 ADRB2 (0.50) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL1549219 0.83 LMNA (0.39) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL31084764 0.83 ADRB2 (0.53) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL3182327 0.83 ADRB2 (0.53) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL3920493 0.82 ADRB2 (0.56) ADRB2ADRB1AOC3HIF1ACYP2D6
SCHEMBL3487656 0.82 AOC3 (0.61) ADRB2ADRB1AOC3HIF1ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014097137-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEIZURES AND NEUROLOGIC DISEASES KANDULA MAHESH (IN) 2014-06-26 WO claimed
EP-2968211-B1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO PHARM SOLUTIONS CO LTD (KR) 2021-05-12 EP disclosed
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
US-9504668-B2 Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-29 US disclosed
CN-104136416-B Phenylalkylamino carbamate derivatives compound and comprise the pharmaceutical composition of this Phenylalkylamino carbamate derivatives compound 比皮艾思药物研发有限公司 2016-11-09 CN disclosed
US-20160097063-A1 Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-04-07 US disclosed
US-20160097063-A1 Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-04-07 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-01-28 US disclosed
US-9029589-B2 Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-05-12 US disclosed
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2013-06-27 US disclosed
EP-0907635-B1 HALOGEN SUBSTITUTED CARBAMATE COMPOUNDS FROM 2-PHENYL-1,2-ETHANEDIOL SK CORP (KR) 2002-09-25 EP disclosed
US-20010034365-A1 Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol CHOI YONG MOON (US) 2001-10-25 US disclosed
US-6127412-A TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY AS ANTICONVULSANTS, ANTIEPILEPTIC AND NEUROPROTECTIVE AGENTS AND CENTRALLY ACTING MUSCLE RELAXANTS SK CORPORATION (US) 2000-10-03 US disclosed
US-6103759-A COMPRISING PURE ENANTIOMERIC FORMS, AS WELL AS ENANTIOMERIC MIXTURES, OF (2-(2-CHLOROPHENYL)-2-HYDROXYETHYL)OXYCARBOXAMIDE; USEFUL FOR TRATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SK CORPORATION (US) 2000-08-15 US disclosed
EP-0907635-A1 HALOGEN SUBSTITUTED CARBAMATE COMPOUNDS FROM 2-PHENYL-1,2-ETHANEDIOL SK Corporation (KR) 1999-04-14 EP disclosed
US-5854283-A Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol YUKONG LIMITED (KR) 1998-12-29 US disclosed
US-5698588-A OPTICALLY PURE ENANTIOMERIC FORM; TREATING CENTRAL NERVOUS SYSTEM DISORDERS YUKONG LIMITED (KR) 1997-12-16 US disclosed
WO-1997026241-A1 HALOGEN SUBSTITUTED CARBAMATE COMPOUNDS FROM 2-PHENYL-1,2-ETHANEDIOL SK CORPORATION (KR) 1997-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034365-A1 Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol DDT, GRIK2, GABRD ADRB2 1524/4885ADRB1 2339/4885AOC3 1009/4885
US-20130165509-A1 PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME MYLK, PDE3A, TNNC1 ADRB2 864/4885ADRB1 929/4885AOC3 3584/4885
US-20160023999-A1 PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME SCN1A, GABARAPL1, NAA10 ADRB2 4257/4885ADRB1 3917/4885AOC3 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.